HSV Testing Market Report Scope & Overview:

The HSV Testing Market was valued at USD 0.66 Billion in 2025 and is expected to reach USD 1.19 Billion by 2035, growing at a CAGR of 6.12% from 2026 to 2035.

The HSV Testing Market is growing steadily owing to the high prevalence of infections with Herpes Simplex Virus, increasing awareness about sexually transmitted diseases, and growing need for early and reliable diagnosis. The increased use of molecular diagnostic techniques and point of care testing devices has made the process of diagnosis more efficient. Moreover, increased screening programs, increased investment in the healthcare sector, and emphasis on preventive healthcare measures are helping the market to grow. Along with that, availability of self-test kits, improvements in healthcare infrastructure, and government programs related to infection control are helping market to grow.

According to the World Health Organization (WHO), approximately 67% of the global population under the age of 50 carries HSV-1 infection, while nearly 13% of individuals aged 15–49 worldwide are living with HSV-2 infection, one of the most prevalent sexually transmitted infections globally. These high infection rates are significantly increasing demand for reliable, rapid, and accurate HSV diagnostic testing solutions across hospitals, diagnostic laboratories, and sexual health clinics worldwide.

Market Size and Forecast

• Market Size in 2026E: USD 0.70 Billion

• Market Size by 2035: USD 1.19 Billion

• CAGR: 6.12% from 2026 to 2035

• Fastest Growing Region: Asia Pacific

• Largest Region: North America

HSV Testing Market Trends

• Rising prevalence of herpes simplex virus (HSV) infections and increasing awareness of sexually transmitted diseases are driving the HSV testing market.

• Growing adoption of molecular diagnostics, serology tests, and point-of-care testing is boosting market growth.

• Expansion of diagnostic laboratories, sexual health clinics, and hospital testing services is fueling demand.

• Increasing focus on early detection, accurate diagnosis, and infection management is shaping adoption trends.

• Advancements in PCR-based assays, rapid testing kits, and automated diagnostic platforms are enhancing testing accuracy and turnaround time.

The U.S. HSV Testing Market Outlook

The U.S. HSV Testing Market was valued at approximately USD 0.22 Billion in 2025 and is expected to reach approximately USD 0.42 Billion by 2035, growing at a CAGR of approximately 6.68%.

The United States accounts for the world's largest national HSV testing market, driven by the country's well-developed sexual health clinical infrastructure, high STI testing volumes across both public health and private laboratory channels, active public health messaging around STI awareness and regular testing, and the FDA's progressive engagement with HSV diagnostic product development through its 510(k) clearance pathway. The CDC's STI screening recommendations, which include type-specific HSV serological testing in relevant clinical contexts, provide the clinical guideline foundation that drives physician HSV testing behaviour across primary care, obstetrics and gynaecology, infectious disease, and sexual health specialist settings.

According to the U.S. Centers for Disease Control and Prevention (CDC), nearly 1 in 6 people aged 14–49 in the United States are affected by genital HSV-2 infection, while millions of new HSV infections occur annually, creating substantial demand for herpes simplex virus diagnostic testing and screening solutions.

HSV Testing Market Segment Analysis

• By Type, HSV-1/HSV-2 Combines segment dominated the HSV Testing Market in 2025 with 52% share; HSV-2 segment is the fastest growing segment.

• By Sample Type, Blood segment dominated the market in 2025 with 48% share; Swabs segment is the fastest growing segment

• By Test Type, Serological Tests segment dominated the HSV Testing Market in 2025 with 46% share; Point-of-care Tests segment is the fastest growing segment.

• By End Use, Hospitals segment dominated the market in 2025 with 44% share; Home Care / Self-testing segment is the fastest growing segment.

By Type, HSV-1/HSV-2 combines segment dominated the hsv testing market, hsv-2 segment is the fastest growing

HSV-1/HSV-2 Combined segment dominated the HSV Testing market owing to the rising inclination towards comprehensive testing options that could detect both the viruses at once. Combination testing is preferred among the healthcare professionals since it leads to greater diagnostic precision, shorter testing time, and helps plan for treatments effectively. With rising awareness about the spread of sexually transmitted infections and increasing screening efforts, the adoption of the product will continue rising.

HSV-2 segment is the fastest growing due to the growing prevalence of genital herpes infections and awareness among people regarding the detection of sexually transmitted diseases. The rising requirement for an early and precise diagnosis is prompting healthcare providers to opt for such testing procedures. Public health campaigns regarding STIs detection are adding to its momentum.

By Sample Type, blood segment dominated the HSV testing market, swabs segment is the fastest growing

Blood segment dominated the market owing to its high reliability and extensive usage for conducting serological tests to diagnose HSV. Blood is an ideal source to detect the presence of antibodies and ensure proper diagnosis even before the symptoms become visible. It is favored by hospitals and diagnostic centers for conducting reliable tests owing to the standardized sample collection process. Increased screenings and higher volumes of diagnostic tests drive the dominance of the segment worldwide.

Swabs segment is the fastest growing owing to the increasing preference for quick and targeted sample collection procedures. Swab samples are highly useful in diagnosing active HSV lesions, and their usage is increasing in molecular diagnostic tests. They have proven to be easy to collect, non-invasive, and accurate in detecting viral shedding. The increased adoption of POC tests at home and hospital settings is expected to increase growth rates even further.

By Test Type, serological tests segment dominated the HSV testing market, point-of-care tests segment is the fastest growing

Serological Tests segment dominated the HSV Testing market owing to their cost-effectiveness, wide reach, and high capacity to identify the presence of HSV antibodies among the population. Serological tests are widely preferred by hospitals and laboratories for screening and epidemiological purposes. With serological tests, detection and management of both past and present infections can be enhanced. Awareness about sexually transmitted infections and increased screening activities drive adoption of this segment.

Point-of-care Tests segment is the fastest growing owing to the increasing need for fast and convenient testing options. Point-of-care tests provide instant diagnosis results and help make quick decisions. In addition to technological advances in portable diagnostic devices, the growing inclination toward convenience drives growth in the segment. Increasing awareness about timely diagnosis of STIs boosts the segment globally.

By End Use, hospitals segment dominated the HSV testing market, home care / self-testing segment is the fastest growing

Hospitals segment dominated the market because of the high number of patients, highly developed diagnostic facilities, and the presence of skilled healthcare professionals. Hospitals carry out a substantial amount of HSV tests for the purpose of diagnosis and treatment of the disease. The use of modern molecular and serological testing devices helps the hospitals in their leadership. Increasing cases of sexually transmitted diseases and the rising number of testing programs in hospitals are further fueling the demand for the products.

Home Care / Self-testing segment is the fastest growing because of the rising preference of consumers for accessible and convenient testing services. Rising awareness about the importance of sexual health and acceptance of self-testing services have been driving the demand for the products. Advancements in user-friendly kits and technological innovations in home-based testing technologies have helped the segment gain prominence among consumers.

Regional Analysis

North America HSV Testing Market Insights

North America dominated the global HSV Testing market in 2025, holding approximately 38.30% of global revenues, with the United States accounting for approximately 82.47% of regional revenue. The region's leadership reflects its high STI prevalence burden, well-developed clinical laboratory infrastructure including both hospital and independent laboratory networks, active public health STI testing campaigns, and the commercial maturity of its sexual health diagnostics market whose product innovation pipeline is the most active globally. Canada contributes supplementary regional demand through its provincially funded public health laboratory networks and growing adoption of molecular HSV testing across its sexual health and prenatal screening programmes.

The CDC also reports more than 2.4 million combined cases of syphilis, gonorrhea, and chlamydia annually in the U.S., which is increasing the adoption of comprehensive sexually transmitted infection (STI) panel testing that frequently includes HSV diagnostics. Growing STI prevalence, expanding public awareness programs, and increasing use of molecular diagnostic technologies are further supporting the expansion of the HSV testing market across the country.

Europe HSV Testing Market Insights

Europe held approximately 24.73% of global HSV Testing revenues in 2025. Germany, France, the United Kingdom, the Netherlands, and Sweden are the leading national markets, each operating well-funded public health laboratory systems with active STI screening programmes and strong adoption of molecular diagnostic platforms. Germany accounts for approximately 28.46% of European revenues through its highly sophisticated reference laboratory infrastructure and its clinical leadership in STI diagnostic protocol development. The European Centre for Disease Prevention and Control's STI surveillance programmes generate ongoing institutional testing volume across member states and sustain standardised diagnostic platform adoption that benefits established commercial testing platform providers.

The European Centre for Disease Prevention and Control (ECDC) reports a continued rise in sexually transmitted infection surveillance and testing programs across EU countries, supporting higher adoption of HSV screening and molecular diagnostic technologies.

In addition, Eurostat healthcare data indicates that healthcare expenditure exceeds 10% of GDP in several European countries, enabling continued investment in advanced laboratory infrastructure, molecular diagnostics, and infectious disease testing capabilities, thereby supporting growth in the HSV testing market.

Asia Pacific HSV Testing Market Insights

Asia Pacific is the fastest-growing regional HSV Testing market, projected to expand at a CAGR of approximately 7.84% through 2035. The region's growth is driven by rising STI prevalence documentation, expanding healthcare infrastructure investment, growing sexual health awareness particularly among urban young adult populations, and increasing government STI surveillance programme investment across China, India, Japan, South Korea, and Southeast Asian nations.

China accounts for approximately 36.84% of Asia Pacific revenues through its large population base, expanding molecular diagnostic laboratory network in urban centres, and government infectious disease surveillance programmes that incorporate HSV monitoring. India is growing fastest within the region as its healthcare infrastructure development and growing awareness of STI testing among urban populations create an expanding diagnostic market.

MEA & Latin America HSV Testing Market Insights

Middle East and Latin America are smaller but growing HSV Testing markets where expanding healthcare system capacity, rising STI awareness, and growing public health commitment to sexual health surveillance are creating increasing diagnostic demand. Saudi Arabia leads MEA revenues at approximately 22.47% of the regional total through its well-funded Ministry of Health public health system, its growing private hospital laboratory sector whose diagnostic capabilities increasingly include molecular STI testing panels, and its Vision 2030 healthcare quality improvement programme that is driving investment in diagnostic testing infrastructure across the country's expanding hospital network.

Brazil leads Latin American revenues at approximately 43.84% of the regional total through its large population, well-developed public health laboratory network under the SUS system, active STI testing campaigns in major metropolitan sexual health clinics, and the Brazilian Ministry of Health's sustained investment in STI prevention and surveillance programmes that generate reliable institutional HSV testing demand throughout the forecast period.

Market Dynamics

Growth Drivers: Rising STI awareness, screening mandates, and molecular diagnostics are driving sustained HSV testing market growth.

The high prevalence of Hsv infection around the world, coupled with its asymptomatic characteristics and serious public health implications through unrecognized transmission, will necessitate the continued development of testing technology. Health organizations like WHO, CDC, and ECDC advocate for increased use of HSV typing tests through STI prevention strategies to promote procurement. This will ensure regular testing through clinical applications. HSV testing incorporated in STI panels and antenatal care will ensure the diagnosis becomes standard practice in routine medicine practices. This will ensure easier testing through reduced barriers between patients and clinicians.

Restraints: Debate over asymptomatic screening and HSV-2 false-positive limitations is restricting primary care testing expansion.

The guidelines from leading organizations such as the US Preventive Services Task Force recommend against HSV serology screening for asymptomatic individuals. The reasoning behind this recommendation stems from the possibility of causing unnecessary psychological anxiety as well as the effects that may arise due to the impact on relationships if there are any unexpected or false results obtained. The technical rationale that contributes to this guideline is that commercial HSV-2 IgG tests lack sufficient specificity at low index levels. As a result, there is an increased likelihood of false positive results. As such, this is an important limitation in the amount of screening done in primary care centers.

Opportunities: Home-based testing and digital sexual health platforms are creating new accessible and private diagnostic growth opportunities.

The potential for a home testing product for the detection of HSV is significant and commercially untapped, when considering the vast number of individuals who could benefit from having their HSV status determined but lack access to clinical testing due to reasons such as confidentiality issues, stigma associated with STDs, lack of accessibility, and busy schedules. Platforms like Nurx, Brio, SH24, and Letsgetchecked, which provide mail-order STI tests along with online test results, have shown that there is a consumer willingness to pay for an easy and private HSV test. This makes the commercial viability of such a product possible, both in the form of subscription services and direct-to-consumer tests on demand. The inclusion of the HSV test as part of a package of STIs (such as HIV, chlamydia, gonorrhea, and syphilis) makes it highly appealing as a sexual health panel.

Recent Developments:

• 2026: Qiagen expanded syndromic molecular testing workflows in 2026 by enhancing QIAstat-Dx platform capabilities for sexually transmitted infection testing panels, supporting rapid detection and differentiation of HSV and other pathogens directly from clinical samples in hospital laboratories.

• 2025: Roche Diagnostics expanded cobas HSV 1 and 2 assay availability across additional international markets on its cobas 6800/8800 automated molecular diagnostic platforms, enabling integrated high-throughput HSV PCR testing within existing automated STI testing workflows and supporting both clinical and public health laboratory adoption.

• 2025: Abbott Laboratories launched an updated ARCHITECT HSV-1/2 IgG serological assay with a redesigned index value interpretation algorithm intended to reduce false-positive rates at lower signal-to-cutoff values, addressing a documented clinical accuracy limitation that has historically constrained guideline support for routine asymptomatic population HSV serological screening.

• 2024: Hologic Inc. received additional clearances for HSV target detection within its Panther Fusion multiplex PCR system, enabling simultaneous detection of HSV-1 and HSV-2 alongside other STI and respiratory pathogens in a single-platform fully automated workflow that reduces laboratory complexity for high-volume testing facilities.

• 2024: Roche launched cobas Respiratory flex diagnostic test using new TAGS multiplex PCR technology, enabling simultaneous high-sensitivity detection of multiple viral targets and strengthening molecular testing infrastructure adaptable for infectious disease testing workflows including HSV diagnostics.

HSV Testing Market Key Players are:

• Roche

• Abbott Laboratories

• Becton Dickinson (BD)

• Thermo Fisher Scientific

• Siemens Healthineers

• bioMérieux

• Danaher (Cepheid)

• Qiagen

• Hologic

• Bio-Rad Laboratories

• Grifols

• Meridian Bioscience

• Luminex (DiaSorin)

• QuidelOrtho

• Sekisui Diagnostics

• OraSure Technologies

• GenMark Diagnostics (Roche)

• ELITech Group

• Teco Diagnostics

• NovaTec Immundiagnostica

HSV Testing Market Report Scope: